Uniklinik RWTH Aachen

Futó vizsgálatok

• Toboroz

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· 3. fázis· Forrás

• Toboroz

  Abiomed Impella RT-DAQ - Observational Study

  NCT06308055· Forrás

• Toboroz

  A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

  NCT06780150· Forrás

• Toboroz

  An international trial for children with atypical teratoid/rhabdoid tumours (ATRT)

  2022-501456-28-00· 3. fázis· Forrás

• Toboroz

  High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

  NCT04221035· 3. fázis· Forrás

• Toboroz

  Praegnant Breast Cancer: Early/Advanced/Metastatic

  NCT02338167· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Gyermekkori daganatok3 toboroz
• Akut limfoid leukémia (ALL)1 toboroz
• Áttétes emlőrák1 toboroz
• Neuroblasztóma1 toboroz
• Sclerosis multiplex (SM)1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

  NCT06182085· 2. fázis· Forrás

• Lezárult

  V-A ECMO AUTO Mode Registry

  NCT05759377· Forrás

• Lezárult

  Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)

  2024-515660-31-00· 2. fázis· Forrás

• Lezárult

  Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab

  NCT03480438· 2. fázis· Forrás

• Lezárult

  Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria

  NCT03157635· 1/2. fázis· Forrás

• Lezárult

  Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

  NCT02467270· 2. fázis· Forrás